Ichikawa T - Search Results

1

Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis.

Takeshima F, Matsumura M, Makiyama K, Ohba K, Yamakawa M, Nishiyama H, Yamao T, Akazawa Y, Yamaguchi N, Ohnita K, Ichikawa T, Isomoto H, Nakao K. Takeshima F, et al. Among authors: ichikawa t. Med Sci Monit. 2014 Jul 27;20:1314-8. doi: 10.12659/MSM.890567. Med Sci Monit. 2014. PMID: 25064629 Free PMC article. Clinical Trial.

2

Transactivation of human alpha-fetoprotein gene by X-gene product of hepatitis B virus in human hepatoma cells.

Arima T, Nakao K, Nakata K, Ishikawa H, Ichikawa T, Hamasaki K, Ishii N, Eguchi K. Arima T, et al. Among authors: ichikawa t. Int J Mol Med. 2002 Apr;9(4):397-400. Int J Mol Med. 2002. PMID: 11891535

3

Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.

Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K. Abiru S, et al. Among authors: ichikawa t. Hepatology. 2002 May;35(5):1117-24. doi: 10.1053/jhep.2002.32676. Hepatology. 2002. PMID: 11981761

4

Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults.

Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N. Nakao K, et al. Among authors: ichikawa t. Am J Gastroenterol. 2002 Jul;97(7):1796-801. doi: 10.1111/j.1572-0241.2002.05846.x. Am J Gastroenterol. 2002. PMID: 12135038

5

Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma.

Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K, Eguchi K. Ohkubo K, et al. Among authors: ichikawa t. Cancer. 2002 May 15;94(10):2663-8. doi: 10.1002/cncr.10557. Cancer. 2002. PMID: 12173334 Free article.

6

Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.

Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K. Yanagi K, et al. Among authors: ichikawa t. Int J Oncol. 2003 Feb;22(2):345-51. Int J Oncol. 2003. PMID: 12527933

7

Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene.

Ishikawa H, Nakao K, Matsumoto K, Ichikawa T, Hamasaki K, Nakata K, Eguchi K. Ishikawa H, et al. Among authors: ichikawa t. Hepatology. 2003 Mar;37(3):696-704. doi: 10.1053/jhep.2003.50077. Hepatology. 2003. PMID: 12601367

8

Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.

Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K. Shigeno M, et al. Among authors: ichikawa t. Oncogene. 2003 Mar 20;22(11):1653-62. doi: 10.1038/sj.onc.1206139. Oncogene. 2003. PMID: 12642868

9

Short interfering RNA-directed inhibition of hepatitis B virus replication.

Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Hamasaki K, et al. Among authors: ichikawa t. FEBS Lett. 2003 May 22;543(1-3):51-4. doi: 10.1016/s0014-5793(03)00400-9. FEBS Lett. 2003. PMID: 12753904 Free article.

10

Analysis of anti-HBs levels in healthcare workers over 10 years following booster vaccination for hepatitis B virus.

Nakao K, Hamasaki K, Wakihama N, Maeda M, Ohtsubo N, Sagiike T, Ichikawa T, Ishikawa H, Eguchi K, Ishii N. Nakao K, et al. Among authors: ichikawa t. Vaccine. 2003 Sep 8;21(25-26):3789-94. doi: 10.1016/s0264-410x(03)00313-x. Vaccine. 2003. PMID: 12922112 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,693 results

Search Page

Filters